Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 23 (6), 461-472

Preclinical Insights Into Cholangiopathies: Disease Modeling and Emerging Therapeutic Targets


Preclinical Insights Into Cholangiopathies: Disease Modeling and Emerging Therapeutic Targets

Keisaku Sato et al. Expert Opin Ther Targets.


The common predominant clinical features of cholangiopathies such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and biliary atresia (BA) are biliary damage/senescence and liver fibrosis. Curative therapies are lacking, and liver transplantation is the only option. An understanding of the mechanisms and pathogenesis is needed to develop novel therapies. Previous studies have developed various disease-based research models and have identified candidate therapeutic targets. Areas covered: This review summarizes recent studies performed in preclinical models of cholangiopathies and the current understanding of the pathophysiology representing potential targets for novel therapies. A literature search was conducted in PubMed using the combination of the searched term 'cholangiopathies' with one or two keywords including 'model', 'cholangiocyte', 'animal', or 'fibrosis'. Papers published within five years were obtained. Expert opinion: Access to appropriate research models is a key challenge in cholangiopathy research; establishing more appropriate models for PBC is an important goal. Several preclinical studies have demonstrated promising results and have led to novel therapeutic approaches, especially for PSC. Further studies on the pathophysiology of PBC and BA are necessary to identify candidate targets. Innovative therapeutic approaches such as stem cell transplantation have been introduced, and those therapies could be applied to PSC, PBC, and BA.

Keywords: Cholangiopathy; bile duct; cholangiocyte; inflammation; liver fibrosis.

Conflict of interest statement

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Similar articles

  • Autophagy and Senescence in Fibrosing Cholangiopathies
    Y Nakanuma et al. J Hepatol 62 (4), 934-45. PMID 25435435. - Review
    Fibrosing cholangiopathy such as primary sclerosing cholangitis (PSC) and biliary atresia (BA) is characterized by biliary epithelial injuries and concentric fibrous obli …
  • Cholangiopathies - Towards a Molecular Understanding
    PKH Tam et al. EBioMedicine 35, 381-393. PMID 30236451. - Review
    Liver diseases constitute an important medical problem, and a number of these diseases, termed cholangiopathies, affect the biliary system of the liver. In this review, w …
  • Stress-induced Cellular Responses and Cell Death Mechanisms During Inflammatory Cholangiopathies
    M Sasaki et al. Clin Res Hepatol Gastroenterol 41 (2), 129-138. PMID 27618480. - Review
    Various cellular responses including apoptosis, necrosis, autophagy and cellular senescence are involved in the pathogenesis of inflammatory cholangiopathies, such as pri …
  • The Cholangiopathies
    KN Lazaridis et al. Mayo Clin Proc 90 (6), 791-800. PMID 25957621. - Review
    Cholangiocytes (ie, the epithelial cells that line the bile ducts) are an important subset of liver cells. They are actively involved in the modification of bile volume a …
  • MicroRNAs and Extracellular Vesicles in Cholangiopathies
    P Olaizola et al. Biochim Biophys Acta Mol Basis Dis 1864 (4 Pt B), 1293-1307. PMID 28711597. - Review
    PubMed search (April 2017) was done with the following terms: "microRNA", "miRNA", "miR", "extracellular vesicles", "EV", "exosomes", "primary biliary cholangitis", "prim …
See all similar articles

Cited by 1 PubMed Central articles

LinkOut - more resources